This article introduces a multimodal single-nucleus method to profile gene expression and chromatin marks from frozen tumor biopsies, enabling clinical monitoring of non-genetic tumor heterogeneity. In ovarian cancer patients, it reveals consistent evolution under chemotherapy toward resistant EMT/TNFα programs that are epigenetically primed before treatment, and shows baseline tumor states can predict survival.